Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia.

Sokolov V, Helmlinger G, Nilsson C, Zhudenkov K, Skrtic S, Hamren B, Peskov K, Hurt-Camejo E, Jansson-Lofmark R.

J Lipid Res. 2019 Jul 10. pii: jlr.M092486. doi: 10.1194/jlr.M092486. [Epub ahead of print]

PMID:
31292220
Free Article
2.

Role of T Cell-To-Dendritic Cell Chemoattraction in T Cell Priming Initiation in the Lymph Node: An Agent-Based Modeling Study.

Azarov I, Peskov K, Helmlinger G, Kosinsky Y.

Front Immunol. 2019 Jun 11;10:1289. doi: 10.3389/fimmu.2019.01289. eCollection 2019.

3.

Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology.

Peskov K, Azarov I, Chu L, Voronova V, Kosinsky Y, Helmlinger G.

Front Immunol. 2019 Apr 30;10:924. doi: 10.3389/fimmu.2019.00924. eCollection 2019. Review.

4.

Quantitative Systems Pharmacology: An Exemplar Model-Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development.

Helmlinger G, Sokolov V, Peskov K, Hallow KM, Kosinsky Y, Voronova V, Chu L, Yakovleva T, Azarov I, Kaschek D, Dolgun A, Schmidt H, Boulton DW, Penland RC.

CPT Pharmacometrics Syst Pharmacol. 2019 May 14. doi: 10.1002/psp4.12426. [Epub ahead of print] Review.

5.

Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics.

Mistry HB, Helmlinger G, Al-Huniti N, Vishwanathan K, Yates J.

Cancer Chemother Pharmacol. 2019 Jul;84(1):51-60. doi: 10.1007/s00280-019-03840-3. Epub 2019 Apr 24.

6.

Erratum: Publisher Correction: Mathematical model of hemodynamic mechanisms and consequences of glomerular hypertension in diabetic mice.

Mahato HS, Ahlstrom C, Jansson-Löfmark R, Johansson U, Helmlinger G, Hallow KM.

NPJ Syst Biol Appl. 2019 Mar 4;5:9. doi: 10.1038/s41540-019-0081-8. eCollection 2019.

7.

Mathematical model of hemodynamic mechanisms and consequences of glomerular hypertension in diabetic mice.

Mahato HS, Ahlstrom C, Jansson-Löfmark R, Johansson U, Helmlinger G, Hallow KM.

NPJ Syst Biol Appl. 2018 Dec 10;5:2. doi: 10.1038/s41540-018-0077-9. eCollection 2019. Erratum in: NPJ Syst Biol Appl. 2019 Mar 4;5:9.

8.

Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.

Hallow KM, Greasley PJ, Helmlinger G, Chu L, Heerspink HJ, Boulton DW.

Am J Physiol Renal Physiol. 2018 Nov 1;315(5):F1295-F1306. doi: 10.1152/ajprenal.00202.2018. Epub 2018 Jul 18.

PMID:
30019930
9.

Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: A quantitative assessment using an integrative systems pharmacology model.

Voronova V, Zhudenkov K, Penland RC, Boulton DW, Helmlinger G, Peskov K.

Diabetes Obes Metab. 2018 Aug;20(8):2034-2038. doi: 10.1111/dom.13326. Epub 2018 May 9.

PMID:
29663628
10.

Assessing QT/QTc interval prolongation with concentration-QT modeling for Phase I studies: impact of computational platforms, model structures and confidence interval calculation methods.

Lu J, Li J, Helmlinger G, Al-Huniti N.

J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):469-482. doi: 10.1007/s10928-018-9582-0. Epub 2018 Mar 19.

PMID:
29556866
11.

Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model.

Kosinsky Y, Dovedi SJ, Peskov K, Voronova V, Chu L, Tomkinson H, Al-Huniti N, Stanski DR, Helmlinger G.

J Immunother Cancer. 2018 Feb 27;6(1):17. doi: 10.1186/s40425-018-0327-9.

12.

Integrating dose estimation into a decision-making framework for model-based drug development.

Dunyak J, Mitchell P, Hamrén B, Helmlinger G, Matcham J, Stanski D, Al-Huniti N.

Pharm Stat. 2018 Mar;17(2):155-168. doi: 10.1002/pst.1841. Epub 2018 Jan 10.

PMID:
29322659
13.

Multiscale Mathematical Model of Drug-Induced Proximal Tubule Injury: Linking Urinary Biomarkers to Epithelial Cell Injury and Renal Dysfunction.

Gebremichael Y, Lu J, Shankaran H, Helmlinger G, Mettetal J, Hallow KM.

Toxicol Sci. 2018 Mar 1;162(1):200-211. doi: 10.1093/toxsci/kfx239.

PMID:
29126144
14.

Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.

Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW.

Diabetes Obes Metab. 2018 Mar;20(3):479-487. doi: 10.1111/dom.13126. Epub 2017 Nov 15.

PMID:
29024278
15.

Pharmacometric Modeling of Naloxegol Efficacy and Safety: Impact on Dose and Label.

Al-Huniti N, Zhou D, Xu H, Aksenov S, Bui KH, Fox R, Helmlinger G, Stanski D.

Clin Pharmacol Ther. 2017 Nov;102(5):741-744. doi: 10.1002/cpt.719. Epub 2017 May 26. Review.

PMID:
28548207
16.

Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet.

Helmlinger G, Al-Huniti N, Aksenov S, Peskov K, Hallow KM, Chu L, Boulton D, Eriksson U, Hamrén B, Lambert C, Masson E, Tomkinson H, Stanski D.

Eur J Pharm Sci. 2017 Nov 15;109S:S39-S46. doi: 10.1016/j.ejps.2017.05.028. Epub 2017 May 12. Review.

PMID:
28506868
17.

Interpretation of metabolic memory phenomenon using a physiological systems model: What drives oxidative stress following glucose normalization?

Voronova V, Zhudenkov K, Helmlinger G, Peskov K.

PLoS One. 2017 Feb 8;12(2):e0171781. doi: 10.1371/journal.pone.0171781. eCollection 2017.

18.

Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis.

Hallow KM, Gebremichael Y, Helmlinger G, Vallon V.

Am J Physiol Renal Physiol. 2017 May 1;312(5):F819-F835. doi: 10.1152/ajprenal.00497.2016. Epub 2017 Feb 1.

19.

Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes.

Nyman E, Rozendaal YJ, Helmlinger G, Hamrén B, Kjellsson MC, Strålfors P, van Riel NA, Gennemark P, Cedersund G.

Interface Focus. 2016 Apr 6;6(2):20150075. doi: 10.1098/rsfs.2015.0075. Review.

20.

Implications of Dynamic Occupancy, Binding Kinetics, and Channel Gating Kinetics for hERG Blocker Safety Assessment and Mitigation.

Pearlstein RA, MacCannell KA, Erdemli G, Yeola S, Helmlinger G, Hu QY, Farid R, Egan W, Whitebread S, Springer C, Beck J, Wang HR, Maciejewski M, Urban L, Duca JS.

Curr Top Med Chem. 2016;16(16):1792-818. Review.

PMID:
26975508
21.

A Generic Mechanism for Enhanced Cytokine Signaling via Cytokine-Neutralizing Antibodies.

Shulgin B, Helmlinger G, Kosinsky Y.

PLoS One. 2016 Feb 12;11(2):e0149154. doi: 10.1371/journal.pone.0149154. eCollection 2016.

22.

A mechanistic tumor penetration model to guide antibody drug conjugate design.

Vasalou C, Helmlinger G, Gomes B.

PLoS One. 2015 Mar 18;10(3):e0118977. doi: 10.1371/journal.pone.0118977. eCollection 2015.

23.

Understanding pharmacokinetics using realistic computational models of fluid dynamics: biosimulation of drug distribution within the CSF space for intrathecal drugs.

Kuttler A, Dimke T, Kern S, Helmlinger G, Stanski D, Finelli LA.

J Pharmacokinet Pharmacodyn. 2010 Dec;37(6):629-44. doi: 10.1007/s10928-010-9184-y. Epub 2010 Dec 7.

24.

Modeling and simulation of preclinical cardiac safety: towards an integrative framework.

Soubret A, Helmlinger G, Dumotier B, Bibas R, Georgieva A.

Drug Metab Pharmacokinet. 2009;24(1):76-90. Review.

25.

Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.

Bottino D, Penland RC, stamps A, Traebert M, Dumotier B, Georgiva A, Helmlinger G, Lett GS.

Prog Biophys Mol Biol. 2006 Jan-Apr;90(1-3):414-43.

PMID:
16321428
26.

An integrated approach for inference and mechanistic modeling for advancing drug development.

Aksenov SV, Church B, Dhiman A, Georgieva A, Sarangapani R, Helmlinger G, Khalil IG.

FEBS Lett. 2005 Mar 21;579(8):1878-83. Review.

27.

A skin sensitization safety assessment of a new bleach activator technology in detergent applications.

Roggeband R, Helmlinger G, Smith I, Wilhelm KP, Ryan CA, Gerberick GF.

Contact Dermatitis. 2002 Apr;46(4):211-9.

PMID:
12081699
28.

Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism.

Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK.

Clin Cancer Res. 2002 Apr;8(4):1284-91.

29.

Formation of endothelial cell networks.

Helmlinger G, Endo M, Ferrara N, Hlatky L, Jain RK.

Nature. 2000 May 11;405(6783):139-41. No abstract available.

PMID:
10821260
30.

Solid stress inhibits the growth of multicellular tumor spheroids.

Helmlinger G, Netti PA, Lichtenbeld HC, Melder RJ, Jain RK.

Nat Biotechnol. 1997 Aug;15(8):778-83.

PMID:
9255794
31.
32.
33.

Pulsatile and steady flow-induced calcium oscillations in single cultured endothelial cells.

Helmlinger G, Berk BC, Nerem RM.

J Vasc Res. 1996 Sep-Oct;33(5):360-9.

PMID:
8862141
34.

Calcium responses of endothelial cell monolayers subjected to pulsatile and steady laminar flow differ.

Helmlinger G, Berk BC, Nerem RM.

Am J Physiol. 1995 Aug;269(2 Pt 1):C367-75.

PMID:
7653519
35.

Effects of pulsatile flow on cultured vascular endothelial cell morphology.

Helmlinger G, Geiger RV, Schreck S, Nerem RM.

J Biomech Eng. 1991 May;113(2):123-31.

PMID:
1875686

Supplemental Content

Loading ...
Support Center